Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine

Biochemical Journal

Volumn 375, Issue 2, 2003, Pages 465-470

  Ning, Q U ^a   Ignatenko, Natalia A ^a,b   Yamauchi, Phillip ^a   Stringer, David E ^a   Levenson, Corey ^c   Shannon, Patrick ^c   Perrin, Scott ^d   Gerner, Eugene W ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c Ilex Oncology Inc   (United States)

^d NOVASEP Inc   (United States)

Author keywords

Difluoromethylornithine enantiomer; Enzyme inactivation parameter; Ornithine decarboxylase; Polyamine

Indexed keywords

BIOSYNTHESIS; COMPLEXATION; ENZYME INHIBITION; ENZYME KINETICS; GROWTH KINETICS; TUMORS;

CELL GROWTH;

BIOCHEMISTRY;

ANTIPARASITIC AGENT; DEXTRO EFLORNITHINE; EFLORNITHINE; ENZYME; ORNITHINE; ORNITHINE DECARBOXYLASE INHIBITOR; POLYAMINE; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; CATALYSIS; CELL GROWTH; CELL LINE; CELL MATURATION; COLON TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DECARBOXYLATION; DIALYSIS; DISSOCIATION CONSTANT; DRUG INACTIVATION; DRUG POTENCY; DRUG PURIFICATION; ENANTIOMER; ENZYME ACTIVITY; ENZYME INHIBITOR COMPLEX; ENZYME PURIFICATION; EUKARYOTE; HUMAN; HUMAN CELL; IC 50; MAMMAL CELL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STEREOSPECIFICITY; TOXICITY;

DOSE-RESPONSE RELATIONSHIP, DRUG; EFLORNITHINE; ENZYME INHIBITORS; HUMANS; KINETICS; ORNITHINE DECARBOXYLASE; STEREOISOMERISM; TIME FACTORS;

EUKARYOTA; MAMMALIA;

EID: 0142169526     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20030382     Document Type: Article

References (30)

1. Cohen, S. (1998) A Guide to the Polyamines, Oxford University Press, New York
2. Tabor, H., Hafner, E. W. and Tabor, C. W. (1980) Construction of an Escherichia coli strain unable to synthesize putrescine, spermidine, or cadaverine: characterization of two genes controlling lysine decarboxylase. J. Bacteriol. 144, 952-956
3. Balasundaram, D., Tabor, C. W. and Tabor, H. (1991) Spermidine or spermine is essential for the aerobic growth of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A. 88, 5872-5876
4. Pendeville, H., Carpino, N., Marine, J. C., Takahashi, Y., Muller, M., Martial, J. A. and Cleveland, J. L. (2001) The ornithine decarboxylase gene is essential for cell survival during early murine development. Mol. Cell. Biol. 21, 6549-6558
5. Meyskens, Jr, F. L. and Gerner, E. W. (1999) Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin. Cancer Res. 5, 945-951
6. Pena, A., Reddy, C. D., Wu, S., Hickok, N. J., Reddy, E. P., Yumet, G., Soprano, D. R. and Soprano, K. J. (1993) Regulation of human ornithine decarboxylase expression by the c-Myc. Max protein complex. J. Biol. Chem. 268, 27277-27285
7. Bello-Fernandez, C., Packham, G. and Cleveland, J. L. (1993) The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc. Natl. Acad. Sci. U.S.A. 90, 7804-7808
8. Erdman, S. H., Ignatenko, N. A., Powell, M. B., Blohm-Mangone, K. A., Holubec, H., Guillen-Rodriguez, J. M. and Gerner, E. W. (1999) APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis 20, 1709-1713
9. He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B. and Kinzler, K. W. (1998) Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512
10. Fultz, K. E. and Gerner, E. W. (2002) APC-dependent regulation of ornithine decarboxylase in human colon tumor cells. Mol. Carcinog. 34, 10-18
11. Kuzoe, F. A. (1993) Current situation of African trypanosomiasis. Acta Trop. 54, 153-162
12. Bacchi, C. J., Nathan, H. C., Hutner, S. H., McCann, P. P. and Sjoerdsma, A. (1980) Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210, 332-334
13. Smith, D., Davies, S., Nelson, M., Youle, M., Gleeson, J. and Gazzard, B. (1990) Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy. AIDS 4, 1019-1021
14. Poulin, R., Lu, L., Ackermann, B., Bey, P. and Pegg, A. E. (1992) Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by α-difluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme binding sites. J. Biol. Chem. 267, 150-158
15. Grishin, N. V., Osterman, A. L., Brooks, H. B., Phillips, M. A. and Goldsmith, E. J. (1999) X-ray structure of ornithine decarboxylase from Trypanosoma brucei: the native structure and the structure in complex with α-difluoromethylornithine. Biochemistry 38, 15174-15184
16. Coleman, C. S., Stanley, B. A. and Pegg, A. E. (1993) Effect of mutations at active site residues on the activity of ornithine decarboxylase and its inhibition by active site-directed irreversible inhibitors. J. Biol. Chem. 268, 24572-24579
17. Danzin, C., Schirlin, D. and Wagner, J. (1987) Biochemistry of vitamin B6. In Proceedings of the 7th International Congress on Chemical and Biological Aspects of Vitamin B Catalysis, vol. 2 (Korpela, T. and Christen, P., eds.), pp. 333-336, Birkhauser Congress Reports. Life Sciences, Springer Verlag, Basel
18. Doyle, K. J., McLaren, C. E., Shanks, J. E., Galus, C. M. and Meyskens, F. L. (2001) Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions. Arch. Otolaryngol. Head Neck Surg. 127, 553-558
19. McWilliams, M. L., Chen, G. D. and Fechter, L. D. (2000) Characierization of the ototoxicity of difluoromethylornithine and its enantiomers. Toxicol. Sci. 56, 124-132
20. Ludemann-Homburger, O., Nicoud, R. M. and Bailly, M. (2000) The VariCol process: a new multicolumn continuous chromatographic process. Sep. Sci. Technol. 35, 1829-1862
21. Hickok, N. J., Seppanen, P. J., Gunsalus, G. L. and Janne, O. A. (1987) Complete amino acid sequence of human ornithine decarboxylase deduced from complementary DNA. DNA 6, 179-187
22. Seely, J. E. and Pegg, A. E. (1983) Changes in mouse kidney ornithine decarboxylase activity are brought about by changes in the amount of enzyme protein as measured by radioimmunoassay. J. Biol. Chem. 258, 2496-2500
23. Tome, M. E., Fiser, S. M. and Gerner, E. W. (1994) Consequences of aberrant ornithine decarboxylase regulation in rat hepatoma cells. J. Cell. Physiol. 158, 237-244
24. Seiler, N. and Knodgen, B. (1980) High-performance liquid chromatographic procedure for the simultaneous determination of the natural polyamines and their monoacetyl derivatives. J. Chromatogr. 221, 227-235
25. Kitz, R. and Wilson, I. B. (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J. Biol. Chem. 237, 3245-3249
26. Shapiro, J. and Lui, H. (2001) Vaniqa-eflornithine 13.9% cream. Skin Therapy Lett. 6, 1-3 and 5
27. Metcalf, B. W., Bey, P., Danzin, C., Jung, M. J., Cagara, P. and Ververt, J. P. (1978) Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C. 4.1.1.17) by substrate and product analogues. J. Am. Chem. Soc. 100, 2551-2553
28. Alberts, D. S., Dorr, R. T., Einspahr, J. G., Aickin, M., Saboda, K., Xu, M. J., Peng, Y. M., Goldman, R., Foote, J. A., Warneke, J. A. et al. (2000) Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-DL- ornithine. Cancer Epidemiol. Biomarkers Prev. 9, 1281-1286
29. Einspahr, J. G., Nelson, M. A., Saboda, K., Warneke, J., Bowden, G. T. and Alberts, D. S. (2002) Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. Clin. Cancer Res. 8, 149-155
30. Meyskens, Jr, F. L., Emerson, S. S., Pelot, D., Meshkinpour, H., Shassetz, L. R., Einspahr, J., Alberts, D. S. and Gerner, E. W. (1994) Dose de-escalation chemoprevention trial of α-difluoromethylornithine in patients with colon polyps. J. Natl. Cancer Inst. 86, 1122-1130